Kornimate/medical-research-clean huggingface dataset:
long covid-19 fatigue and obstructive sleep apnea

Conditions: Long COVID; Fatigue; Obstructive Sleep Apnea of Adult

Summary: identify the relationship of obstructive sleep apnea (osa) prevalence with post-covid-19 fatigue that remains at least six months after acute disease

the presence of fatigue symptoms up to 6-7 months after acute covid-19 disease, similar to myalgic encephalomyelitis/chronic fatigue syndrome, also observed after other viral infections, have been reported as the most frequent post-covid-19 symptom (townsend et al., 2020). there is a physiological plausibility for osa being a causal factor to covid-19 morbidity and fatigue symptoms by nocturnal hypoxemia, exacerbating or causing endothelial dysfunction, inflammation, oxidative stress, microaspiration and cardiac dysfunction. osa activates the renin-angiotensin-aldosterone system (raas) and angiotensin-converting enzyme-2 (ace2), which is the sars-cov-2 entry receptor in the cells (miller et al., 2021). in this study we will identify the prevalence of osa and it's relation with post-covid-19 fatigue that remains for at least six month after the acute disease, in patients that attend the post-covid-19 out patients hospital clinics. it will be studied also the relation between fatigue and vaccination status, nocturnal hypoxemia, day time sleepness and the acute covid-19 severity. data collection will be performed by a questionnaire administered by qualified clinical study staff (i.e., by physicians who conduct the post-covid-19 medical consultation). demographic, clinical data and clinical research forms will be collected between 6-7th month after the diagnosis of covid-19 (t1) and 9 months later (t2). fatigue will be assessed using the chalder fatigue scale - cfq-11 (chalter et al., 1993). the evaluation of osa related daytime sleepiness will be measured using the epworth sleepiness scale - ess (johns, 1991). the osa diagnosis will be performed using portable monitoring device type iii (in-home polygraphy), between 6-7th month after the diagnosis of covid-19 (t1).

Eligibility criteria:
inclusion criteria: (1) ≥18 years; (2) previous covid-19 at least six months before the initial study protocol evaluation; (3) persistent symptoms after cure criteria defined by who; (4) patients who attend the post-covid-19 follow-up consultation of the study centers. (5) sars-cov-2 infection confirmed by a positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab (6) patients who agree to sign the written informed consent (following the ethics committee protocol). exclusion criteria: (1) patients who had a concomitant neurological disorder that could increase osa risk (such as stroke, parkinson disease, or amyotrophic lateral sclerosis); (2) patients who were on invasive mechanical ventilation. (3) patients with persistent fatigue symptoms,6 months before sars-cov-2 infection (4) patients without sars-cov-2 positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab

Keywords: post-covid-19 fatigue sleep apnea sars-cov-2 vaccines
antidiabetic potiential of moringa and dom extract

Conditions: Diabetes

Summary: the antidiabetic potential of hyphaene thebaica fruits and moringa oleifera leaves will be investigated in diabetic patients (type 2). the patients will be maintained on tea of both drugs for 6 weeks. the fasting blood glucose levels of patients will be checked on a daily basis. other blood biomarkers will be also reported such as insulin concentration, lipid profile, liver enzymes, c-peptide and glycated hemoglobin


Eligibility criteria:
inclusion criteria: * diabetic patients type 2 exclusion criteria: * liver failure * heart failure * renal failure
effects of atypical antipsychotics on appetite and eating behavior of schizophrenia patients

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: in this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.

this is an observational study. 2 self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. we are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.

Eligibility criteria:
inclusion criteria: 1. patients meeting the dsm-iv criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder 2. male and female patients aged 19\~59 3. patients receiving monotherapy with one of the three aaps, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months 4. patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics 5. clinically stable and able to complete the questionnaires 6. patients who sufficiently understand the objective of the study and sign informed consent form exclusion criteria: 1. patients having any medical illness or taking any medicine affecting appetite and body weight 2. patients with severe and unstable medical, neurological or systemic illnesses 3. patients having any comorbid psychiatric disorders including substance use disorders and eating disorders. 4. pregnant or breast-feeding women

Keywords: schizophrenia atypical antipsychotics appetite eating behavior
prenatal diagnosis of antenatal midgut volvulus: specific ultrasound features

Conditions: Fetal Volvulus; Midgut Volvulus

Summary: objective: the small bowel volvulus is a rare cause of intestinal obstruction which may occur in utero and whose prenatal diagnosis is difficult.sonographic signs are mainly indirect and non specific.the aim of this study is to present a retrospective analysis of prenatal sonographicfindings in fetal segmental midgut volvulus.thanks to this series the investigators could highlight the more specifics signs of the volvulus included a new pattern.

objective: the small bowel volvulus is a rare cause of intestinal obstruction which may occur in utero and whose prenatal diagnosis is difficult. sonographic signs are mainly indirect and nonspecific. the aim of this study is to present a retrospective analysis of prenatal sonographic findings in fetal segmental midgut volvulus. thanks to this series the investigators could highlight the more specifics signs of the volvulus included a new pattern. methods: unicentric retrospective analysis of cases of prenatal midgut volvulus between 2006 and 2017. the primary inclusion criteria was postnatal diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings. the exclusion criteria was the absence of prenatal imaging assessment. the investigators collected the clinical history and the echographic mode b and color doppler. they have searched for some specific sign like " whirlpool sign " representing the winding of the mesenteric vein around the superior mesenteric arterywith color doppler with arciform pattern of the midgut, hydro-meconium level in the dilated loops and position of mesenteric vessels for evaluation of the intestinal (mal) rotation. gold standard was surgery or foetopathology if performed.

Eligibility criteria:
inclusion criteria: * postnatal diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings exclusion criteria: * the absence of prenatal imaging assessment

Keywords: midgut volvulus fetal volvulus whirlpool sign pregnant women position of mesenteric vessels post natal surgery foetopathology if performed hydro-meconium level in the dilated loops
evaluation of the effect of ave0657 on obstructive sleep apnea

Conditions: Sleep Apnea, Obstructive

Summary: the primary objective of this study is to assess the activity of 4 escalating doses of ave0657 in comparison to placebo in patients with obstructive sleep apnea hypopnea syndrome.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with obstructive sleep apnea hypopnea syndrome based on international classification of sleep disorders exclusion criteria: * subjects having been treated by continuous positive airway pressure, oral appliance during 4-weeks prior to randomization * chronic respiratory disease or inadequate respiratory parameters * body mass index (bmi) of ≤20 kg/m² or ≥35 kg/m² * surgical procedure to correct apnea within the last three months. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: obstructive sleep apnea
preserve & connect: impact study of the bpc

Conditions: Child Maltreatment; Trauma

Summary: the preserve \& connect project is a multi-site randomized control trial of the breakthrough parenting curriculum: navigating trauma across generations (bpc) in rural and racially and ethnically diverse communities in vermont and connecticut.

the proposed study will determine the efficacy of the bpc at improving the lives of families with a significant history of trauma and establish the evidence base to allow the bpc to be listed on the title iv-e clearing house. the specific research questions that will be answered as are as follows: question 1: does the bpc improve child safety? hypothesis 1a: parents who complete the bpc will have fewer substantiated of child maltreatment as per administrative records. hypothesis 1b: parents who complete the bpc will report less psychologically aggressive and abusive parenting behaviors (parenting scale). question 2: does the bpc improve child permanency? hypothesis 2a: parents who complete the bpc will have fewer out of family placements and placement disruptions as per administrative records. hypothesis 2b: parents who complete the bpc will have stability or permanency with their family of origin as per administrative records. question 3: does the bpc improve child well-being? hypothesis 3: parents who complete the bpc will report improved behavioral and emotional functioning of their children (strength and difficulties questionnaire). question 4: does the bpc improve adult well-being? hypothesis 4a: parents who complete the bpc will report improved use of parenting practices to improve the functional relationship with their children (parenting self-efficacy scale; parent stress index, parent-child relationship scales). hypothesis 4b: parents who complete the bpc will report improved understanding of the influence of trauma on their parenting behaviors and wellness (trauma-informed knowledge and parenting skills survey). question 5: are the improvements of the bpc associated with demographic factors? exploratory analysis 5a: examine the association between measures of child safety, child well-being, child permanency, and adult well-being and measures of acculturation. exploratory analysis 5a: examine the association between measures of child safety, child well-being, child permanency, and adult well-being and measures of acculturation

Eligibility criteria:
inclusion criteria: - parents involved in, or at risk of involvement in, the child welfare system. exclusion criteria: * active psychosis without medication stabilization * ongoing major depressive episodes * active suicidal ideation * active homicidal ideation
pilot study of the safety and efficacy of anakinra (recombinant human interleukin-1 receptor antagonist) in heart failure

Conditions: Heart Failure

Summary: this is an open-label, non-randomized, pilot-study to evaluate the effect of interleukin-1 blockade on exercise capacity in patients with heart failure. subjects will undergo cardiopulmonary exercise testing at baseline and after 2-weeks treatment with anakinra (recombinant human interleukin-1 receptor antagonist).


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of heart failure * recent echocardiogram documenting left ventricular ejection fraction \<40% * high sensitivity c-reactive protein \>2 mg/l. exclusion criteria: * recent changes (previous 3 months) in hf maintenance medications (beta-blockers, angiotensin converting enzyme \[ace\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics) * hospitalization for worsening hf or acute decompensated hf within the previous 12 months * anticipated need for cardiac resynchronization therapy (crt) or automated-implantable cardioverter defibrillator (aicd) * angina or electrocardiograph (ecg) changes that limit maximum exertion during cardiopulmonary exercise testing or baseline ecg changes that limit the ability to detect ischemia (i.e. left bundle-branch block). * recent (\<14 days) use of anti-inflammatory drugs (not including nsaids), chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, active infection, or any comorbidity limiting survival or ability to complete the study * severe kidney dysfunction (egfr \<30 ml/min) * coagulopathy (inr \>1.5), thrombocytopenia (\<50,000/mm3), or leukopenia (absolute neutrophil count \<1,500/mm3) * pregnancy (female patients will be required to take a urine pregnancy test) * latex or rubber allergy * inability to give informed consent

Keywords: heart failure inflammation interleukin-1 cardiopulmonary exercise
evaluating an intervention for physician burnout

Conditions: Physician Burnout

Summary: the goals of this randomized controlled trial are 1) to test the efficacy of an app-based program in reducing physician burnout vs. no app (control) in 100 physicians; 2) to explore the role of an online live training to augment outcomes and develop an ongoing and sustainable support community with a subsample of physicians.


Eligibility criteria:
inclusion criteria: 1. being a physician 2. able to speak english because all study activities will be conducted in english. 3. 18+ years 4. direct patient care exclusion criteria: 1. if using psychotropic medication - not on a stable dosage at least 6 weeks

Keywords: burnout physicians app-based smarthphone mindfulness
cost-effectiveness of tpmt pharmacogenetics

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis

Summary: the purpose of this study is to determine whether thiopurine s-methyltransferase (tpmt) genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel disease (ibd) in need of immune suppression. the study is designed to test the hypothesis that optimization of initial thiopurine dose based on pre-treatment tpmt genotyping will maximize treatment efficacy and minimize adverse drug reactions (adrs) resulting in reduced costs.

immunosuppressives, e.g. azathioprine (aza) and 6-mercaptopurine (6-mp), are important in induction of remission and long term treatment of (ulcerative) colitis and crohn's disease when treatment with 5-aminosalicylates and corticosteroids fails. adrs to immunosuppressive treatment, including myelosuppression and hepatotoxicity, are frequently (15-30%) observed. genetic variation in the tpmt gene results in 10-11% of the general population in reduced and in 0.3-0.6% to negligible tpmt enzyme activity. in ibd patients, this genetic variation predicts 25-40% of the haematological adrs necessitating tempering of thiopurine dose or discontinuation of treatment. pharmacogenetics aims at providing optimized drug treatment to patients by maximizing efficacy and minimizing adverse drug reactions (adrs) based on genetic testing. despite the proven value of pharmacogenetics in clinical practice, its use in medical care is still limited. the best-established example of a pharmacogenetic test is genotyping of thiopurine s-methyltransferase (tpmt) in the treatment of patients with immunosuppressive thiopurines. nonetheless, it is not used on a large scale in clinical practice so far, which might be due to: insufficient information transfer from research to clinic; lack of cost-effectiveness analyses (ceas); lack of availability of (or access to) fast and/or cheap genotyping; or lack of test reimbursement by health insurance.

Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosis of a form of ibd * indication for azathioprine/6-mp treatment * patient giving (written) informed consent exclusion criteria: * previous treatment with azathioprine/6-mp * co-prescription of allopurinol (this treatment blocks xanthine oxidase, an enzyme important for thiopurine metabolism) * baseline leukocyte count less then 3x10\^9 per litre * reduced liver function at baseline * reduced renal function at baseline * known tpmt phenotype (enzyme activity / therapeutic drug monitoring) or genotype * pregnancy or breastfeeding

Keywords: pharmacogenetics cost effectiveness inflammatory bowel diseases crohn disease ulcerative colitis randomized controlled trials
influence of equilibration rate constant (ke0) of propofol on the effect site concentration for loss of consciousness

Conditions: General Anesthesia

Summary: the aim of this study is to validate that an effect compartment concentration for loss of consciousness (loc) was varied according to different keo value.


Eligibility criteria:
inclusion criteria: * adult patients undergoing general anesthesia exclusion criteria: * hepatic or renal disease * drug addiction
health in smart rurality: impact on coordination of care of telemonitoring and data centralization of frailty patients

Conditions: Chronic Obstructive Pulmonary Disease; Heart Failure

Summary: chronic diseases are frequent (around 10% of the total population and 30% after 60 years) and accelerate age-related functional decline. concerning cross-border patients, use of health services can be delayed given the distances, the lack of rapid road access and the limited availability of public transport and the complex organization of coordinated care. one of the ways to reduce acute exacerbations and preserve the quality of life of patients is to detect warning signs early. one of the ways to do this is to use new communication technologies.

the aim of the study is to assess feasibility of using a connected tablet to assess clinical parameters with an alert system in frailty patients aged over 60, living at home, with heart failure and / or chronic obstructive pulmonary disease, potentially requiring care cross-border (france and belgium).

Eligibility criteria:
inclusion criteria: * patients aged over 60 * patients living at home * patients with heart failure and / or chronic obstructive pulmonary disease, * patients potentially requiring care cross-border (france and belgium). * patients agreeing to participate to the study exclusion criteria: * patients who do not speak french * patients with severe cognitive impairment

Keywords: chronic diseases aging people cross-border care new communication technology
validation of a specific measure for assessment of compliance with treatment in patients with hemophilia

Conditions: Haemophilia

Summary: research project for validation of a questionnaire on compliance to treatment in patients with hemophilia. it is intended to validate the american veritas-pro scale according to the international methodology validation questionnaires: reverse translation, according to intersubject patients, psychometric validation and reliability analysis with large sample of patients.

the validated questionnaire obtained in this project will identify the actual degree of patient compliance to drug therapy, using as gold standard the difference between the treatment prescribed and administered.

Eligibility criteria:
inclusion criteria: * patients with hemophilia a and b * patients who have previously signed the informed consent document exclusion criteria: * patients with other congenital coaghulopatías (eg, von willebrand's disease) * patients with cognitive impairment, or oral or written understanding

Keywords: haemophilia adherence of treatment knowledge of illness medical-patient relationship illness behavior treatment difficulties veritas
heart-focused breathing in alzheimer's disease caregivers

Conditions: Burnout, Caregiver; Quality of Life

Summary: this research study will explore the effects of an online heart-focused breathing intervention on 20 informal caregivers of patients with alzheimer's disease (ad) over a period of two weeks.

informal caregivers are often live-in, unpaid spouses, relatives, partners, or friends that help with a loved one's activities of daily living. as a result of caring for a person with alzheimer's disease (ad), many informal caregivers experience caregiver burden. the demanding physical, emotional, and financial responsibilities to care for an ad patient can be detrimental to the caregiver's health. a group of 20 men and women who consider themselves the primary caregiver of a person with ad will be recruited and enrolled into the study. participants will be randomized into one of two study arms, (a) the modified-waitlist control arm or (b) the intervention arm. the study will explore the effects of an online heart-focused breathing intervention on heart rate variability (measured by the welltory app on their smart device), perceived burden, stress, and quality of life in the intervention arm over a two-week period.

Eligibility criteria:
inclusion criteria: * male or female * 18 years of age or older * live-in and unpaid informal caregiver to a loved one with alzheimer's disease * provides care or supervision for at least 4 hours per day for more than 6 months * experiencing stress exclusion criteria: * caregivers who report a low risk assessment score and/or report a medically diagnosed arrhythmia or have a pacemaker will be excluded

Keywords: stress caregiver burden alzheimer's disease caregiver informal caregiver anxiety heart-focused breathing
a crossover safety study of ferumoxytol versus placebo

Conditions: Anemia

Summary: this crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.

this is a double-blind, placebo controlled, crossover design study of the safety of ferumoxytol compared to placebo. patients are randomized to receive either one 510 mg dose of ferumoxytol or the equivalent volume of normal saline followed by the other test article given one week later.

Eligibility criteria:
inclusion criteria: * male or female patients \> 18 years. * have chronic kidney disease per k/doqi guidelines. * baseline hemoglobin of \> 9.0 and \< 12.5 g/dl exclusion criteria: * women who are pregnant or lactating. * received another investigational drug or device within 30 days. * recent parenteral or oral iron therapy. * patients that have other causes of anemia. * major surgery within 30 days or anticipated or planned surgery during the study. * patients with active infections. * recent blood transfusions. * patients with known allergies to iron products.

Keywords: anemia